altrexone for the treatment of amphetamine dependence: a randomised placebo controlled trial

Addiction Centre Stockholm (Beroendecentrum Stockholm) (Sweden)0 个研究点目标入组 80 人开始时间: 2007年11月16日最近更新: 2019年6月26日

适应症

试验速览

•1. Adult male or female between 18 to 65 years
•2. Written, informed consent to participate
•3. Address and telephone in the Stockholm metropolitan area where the participant can be reached
•4. Amphetamine dependence according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria
•5. Having used amphetamine on a minimum of 12 occasions during the 12 weeks prior to screening
•6. Two consecutive urine tests with no traces of amphetamine following screening

•1. Opiate abuse or dependence
•2. Use of any opiate preparation (legal or illicit) during 30 days prior to screening
•3. Presence of opiates in urine at screening
•4. Other mental disorders than substance abuse/dependence considered to be severe and requiring treatment (dementia, severe depression with suicidal ideation, acute psychotic symptoms, schizophrenia - concurrent pharmacological treatment for depression, and mild psychotic symptoms such as paranoid ideation or other forms of milder delusions for which the patient has some degree of insight do not constitute exclusion criteria)
•5. Ongoing treatment with benzodiazepines
•6. Acute withdrawal symptoms at screening, irrespective of cause
•7. Serious somatic disorder (e.g., cancer, moderate to severe hypertension, advanced atherosclerosis, liver cirrhosis, or other disorders considered to be a risk)
•8. Known hypersensitivity to naltrexone

发起方

Addiction Centre Stockholm (Beroendecentrum Stockholm) (Sweden)